Cost-Effectiveness of Ruxolitinib vs Best Available Therapy in the Treatment of Myelofibrosis in Spain

Journal of Health Economics and Outcomes Research
doi 10.36469/9808
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Columbia Data Analytics

Related search

JAK Inhibition With Ruxolitinib Versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine
Medicine
2012English

Ruxolitinib as an Emerging Treatment in Myelofibrosis

Blood and Lymphatic Cancer: Targets and Therapy
2013English

Definition and Management of Ruxolitinib Treatment Failure in Myelofibrosis

Blood Cancer Journal
OncologyHematology
2014English

Efficacy of Ruxolitinib for Myelofibrosis

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2014English

PCN114 Cost Effectiveness of Adjuvant Cyclophosphamide in the Treatment of Breast Cancer in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Cost-Effectiveness of Dialectical Behaviour Therapy vs. Enhanced Usual Care in the Treatment of Adolescents With Self-Harm

Child and Adolescent Psychiatry and Mental Health
PsychiatryChild HealthMental HealthPediatricsPerinatology
2018English

Cost/Effectiveness of Aripiprazole vs. Olanzapine in the Long-Term Treatment of Schizophrenia

Srpski Arhiv Za Celokupno Lekarstvo
Medicine
2019English

Primary Myelofibrosis Associated Glomerulopathy: Significant Improvement After Therapy With Ruxolitinib

BMC Nephrology
Nephrology
2015English

Critical Appraisal of the Role of Ruxolitinib in Myeloproliferative Neoplasm-Associated Myelofibrosis

OncoTargets and Therapy
OncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy